US 12,268,670 B2
Combination of small molecule CD-47 inhibitors with other anti-cancer agents
Muralidhara Ramachandra, Bangalore (IN); Pottayil Govindan Nair Sasikumar, Bangalore (IN); Girish Chandrappa Daginakatte, Bangalore (IN); and Kiran Aithal Balkudru, Bangalore (IN)
Assigned to AURIGENE ONCOLOGY LIMITED, Karnataka (IN)
Filed by Aurigene Oncology Limited, Karnataka (IN)
Filed on Apr. 25, 2022, as Appl. No. 17/728,325.
Application 17/728,325 is a continuation of application No. 16/678,594, filed on Nov. 8, 2019, granted, now 11,311,517.
Claims priority of application No. 201841042108 (IN), filed on Nov. 8, 2018.
Prior Publication US 2022/0241248 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4245 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/4245 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01); C07K 16/2887 (2013.01)] 21 Claims
 
1. A combination comprising a CD47-SIRPα blocking agent and one or more anti-cancer agent(s), wherein the CD47-SIRPα blocking agent is represented by a compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof or an amide thereof or an ester thereof, or a stereoisomer thereof; wherein,
Ra is hydrogen; and R1 represents hydrogen, —(CH2)2CONH2, —(CH2)2COOH, —(CH2)3NHC(═NH)NH2, —(CH2)4NH2, —CH2CONH2, —CH2-aryl, or —CH2-heteroaryl; or Ra and R1, together with the atoms to which they are attached form a pyrrolidine ring;
R2 represents hydrogen, —(CH2)3NHC(═NH)NH2, —(CH2)2CONH2, —(CH2)2COOH, —CH2-aryl, or —CH2-heteroaryl;
Rb and R3, together with the atoms to which they are attached form a pyrrolidine ring.